PLSE
PULSE BIOSCIENCES, INC.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$47.55
+7.02%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$44.58
From 52W high−13.86%
Volume342448.00
Market cap$3.39B
P/E (TTM)—
P/S (TTM)2861.9x
Div yield—
Key dataOct 19, 2026
Open
$44.58
From 52W high
−13.86%
Volume
342448.00
Market cap
$3.39B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−41.4x
P/E (TTM)
—
RSI (14)
44.8
MomentumView details →
1D Return
+7.02%
YTD Return
+241.59%
SummaryUpdated Jun 1, 2026
Pulse Biosciences, Inc. (NASDAQ:PLSE) is a bioelectric medicine company founded in 2014 and headquartered in Hayward, California. Originally incorporated as Electroblate, Inc., the company changed its name to Pulse Biosciences in December 2015 and went public in May 2016. The company has undergone significant strategic evolution, initially focusing on dermatological applications before pivoting to cardiac and soft tissue ablation markets. Pulse Biosciences is currently in the clinical development stage, advancing multiple medical devices based on its proprietary nanosecond Pulsed Field Ablation (nsPFA) technology across three primary therapeutic areas.
Similar companies
Latest newsMore news →
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center covering use of its nPulse Vybrance Percutaneous Electrode System and a clinical collaboration.6d agoPulse Biosciences terminated its at-the-market offering program under its prior equity distribution agreement with TD Securities (USA) LLC dated February 19, 2026.34d agoPulse Biosciences entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent for an at-the-market offering of up to $85 million of common stock.34d ago